NCT05845138View on ClinicalTrials.gov

A Study of SHR-A1811 Combined With Capecitabine in Treatment of Unresectable or Metastatic Breast Cancer With Low HER2 Expression.

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

July 25, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions
Breast Cancer
Interventions
DRUG

SHR-A1811 for injection ; capecitabine

SHR-A1811 for injection; Capecitabine tablets

Trial Locations (9)

100000

RECRUITING

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

110000

NOT_YET_RECRUITING

The First Hospital of China Medical University, Shenyang

210000

NOT_YET_RECRUITING

The First Affiliated Hospital with Nanjing Medical University, Nanjing

230000

NOT_YET_RECRUITING

The Second Hospital of Anhui Medical University, Hefei

250000

NOT_YET_RECRUITING

Shandong Cancer Hospital&Institute, Jinan

325000

NOT_YET_RECRUITING

Wenzhou People's Hospital, Wenzhou

450000

RECRUITING

Henan Provincial People's Hospital, Zhengzhou

515000

NOT_YET_RECRUITING

Shantou Central Hospital, Shantou

530000

NOT_YET_RECRUITING

Guangxi Medical University Affiliated Tumor Hospital & Oncology Medical College, Nanning

All Listed Sponsors
lead

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

INDUSTRY